Review
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Nov 10, 2015; 6(15): 1285-1295
Published online Nov 10, 2015. doi: 10.4239/wjd.v6.i15.1285
New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders
Nigel Irwin, Peter R Flatt
Nigel Irwin, Peter R Flatt, SAAD Centre for Pharmacy and Diabetes, University of Ulster, Coleraine BT52 1SA, Northern Ireland, United Kingdom
Author contributions: All authors contributed to the manuscript.
Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Nigel Irwin, SAAD Centre for Pharmacy and Diabetes, University of Ulster, Cromore Road, Coleraine BT52 1SA, Northern Ireland, United Kingdom. n.irwin@ulster.ac.uk
Telephone: +44-28-70324574 Fax: +44-28-70323939
Received: May 20, 2015
Peer-review started: May 21, 2015
First decision: September 17, 2015
Revised: September 25, 2015
Accepted: October 20, 2015
Article in press: October 27, 2015
Published online: November 10, 2015
Core Tip

Core tip: Stable gut hormones have well defined therapeutic actions for type 2 diabetes mellitus. In addition, simultaneous modulation of gut hormone receptors could increase therapeutic efficacy, but timing and receptor activation profile may be important. Finally, gut-derived peptides could possess benefits for bone disorders, cognitive impairment and cardiovascular dysfunction.